

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

Index

- abortion
 induced, 116
 spontaneous, 11, 174
- academic underachievement, 96
- acetazolamide, 108
- acetylcholine (ACh), 52
- adolescent girls with epilepsy, 6–8
 adverse effects of AEDs, 93–4
 bone health, 95, 266–7
 contraception, 95
 endocrine effects of AEDs, 94–5
 psychosocial issues, 95–7
 reproductive endocrine dysfunction, 92–3
 seizure control, 95
 transition to adult care, 97
- AEDs. *See* antiepileptic drugs
- affective disorders. *See* mood disorders
- agoraphobia, 5–6
- Aicardi syndrome, 85–6
- airway management, obstetric anesthesia, 207–8
- alexithymia, 28
- alfentanil, 211–13
- allopregnanolone
 catamenial epilepsy, 104–5
 mechanism of brain actions, 59–60, 62
 mediating progesterone actions, 58–60
- amenorrhea, hypothalamic.
 See hypothalamic hypogonadism
- androgenic neurosteroids, 53–60, 62
- androstenediol, 61
- anesthesia, obstetric.
 See obstetric anesthesia
- anesthetic induction agents, 209–10
- anovulatory cycles (inadequate luteal phase; ILP), 102–3, 106–7
- antenatal management, 184–6
 AED therapy, 175, 184
- anticholinesterases, 211
- anticonvulsant drugs.
 See antiepileptic drugs
- antidepressants, seizure risks, 28–9
- antidiuretic hormone (ADH), 75–6
- antiepileptic drugs (AEDs)
 adverse effects in children/adolescents, 93–4
 antenatal management, 175, 184
 assessing exposure of breastfed infants, 224–35
 bone health effects, 264–71
 breastfeeding and, 14, 149–50, 223–40
 childhood and adolescent epilepsy, 95
 contraceptive choice and, 135–6
 contraceptive interactions, 10, 128, 132–7
 cyclical use, catamenial epilepsy, 107–8
 domperidone interactions, 240
 endocrine effects in children/adolescents, 94–5
 enzyme-inducing.
 See enzyme-inducing antiepileptic drugs
 excretion into breast milk, 224–5
 fetal adverse effects, 11–12, 183–4, 252, 256–7
 fracture risk and, 266
 hormones and, 61–2, 65–76
 incidence of use in pregnancy, 251
 intrapartum therapy, 177, 186
 kinetics during pregnancy, 177–80
 metabolizing enzymes, 227–8
 neonatal withdrawal symptoms, 256
 obstetric anesthesia and, 208–9
- osteoporosis risk, 15
- perimenstrual changes in metabolism, 105–6
- polytherapy. *See* polytherapy
- postpartum kinetics, 216–20
- preconception management, 138, 150–2, 175
- pregnancy outcomes and, 12–13
- and pregnancy registers, 144, 165–6
- in psychiatric comorbidities, 30
- psychiatric side effects, 28, 31
- psychotropic drug interactions, 30–2
- reproductive endocrine function and, 9, 65–71
- risks in pregnancy, 144–8, 157–67, 183–4
- role in infertility, 66, 120–2
- seizure control during pregnancy, 13–14
- selection for women of childbearing age, 123–5
- self-management in postpartum period, 245
- serum level monitoring.
 See therapeutic drug monitoring
- sleep effects, 38
- teratogenicity.
 See teratogenicity of AEDs
- antipsychotic drugs, seizure risks, 28–9
- anxiety, new mothers, 245
- anxiety disorders, 5–6, 24
- aorticaval compression, pregnant uterus, 208
- Apgar scores, 184
- aspiration pneumonitis, obstetric anesthesia, 207
- atracurium, 210–11
- attention deficit hyperactivity disorder (ADHD), 96
- autism spectrum disorders, 163
- autosomal dominant focal epilepsies, 143
- awakening epilepsies, 36

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

276

Index

- barbiturates, induction of
 - anesthesia, 210, *See also* phenobarbital
- behavioral problems,
 - childhood, 94, 96
- benzodiazepines (BZDs)
 - anesthesia induction, 209
 - catamenial epilepsy, 107–8
 - intrapartum therapy, 186
 - neonatal withdrawal syndrome, 209, 236
 - postpartum seizure management, 216
 - teratogenicity, 164, 212
- bilateral periventricular nodular heterotopia, 143
- bipolar disorder, 24–5
- bone, physiology, 265–6
- bone health, 15, 264–71
- bone mineral density (BMD), 265
 - adolescent girls, 95, 266–7
 - effects of AEDs, 266–70
 - factors associated with reduced, 267
 - mechanisms of AED effects, 270
 - postmenopausal women, 268
 - screening, 270–1
 - treatment of reduced, 271
- brain tumors, 197–200
- brain-derived neurotrophic factor (BDNF), 53
- breast milk
 - factors influencing AED excretion into, 224–5
 - indices of AED excretion into, 226–7, 229
- breastfeeding (lactation), 14, 223–40, 254, *See also* postpartum period
 - assessing infant AED exposure, 224–35
 - avoiding sleep deprivation, 247
 - benefits, 224
 - maternal adherence to, 235
 - neuroimaging with contrast agents, 191–2, 202
 - preconception counseling, 149–50
 - psychotropic drugs, 30–1
 - specific AEDs, 236–40
 - treating refractory seizures, 220
- bullying, 96
- calcium homeostasis, 265
- carbamazepine (CBZ)
 - bone health effects, 268, 270
 - breastfeeding mothers, 229, 236
 - cognitive effects of fetal exposure, 147, 257
 - contraceptive interactions, 134
 - hyponatremic effects, 75
 - pharmacokinetics, 177, 225
 - postpartum period, 216
 - reproductive endocrine effects, 66, 69–70, 121
 - teratogenicity, 146, 161
 - thyroid function effects, 74, 94
- catamenial epilepsy, 8, 50, 101–11
 - animal models, 54
 - definition, 106
 - diagnosis, 107
 - hormonal influences, 55–6, 59, 61, 104–5
 - management, 107–11, 137–8
 - menopausal/perimenopausal changes, 261
 - pathophysiology, 104–6
 - patterns, 102, 106–7
 - prevalence, 106
- catheter angiography, 194–5
- cavernous hemangioma, 199
- CDKL5 gene mutations, 80–2
- central nervous system
 - infections, 199
- cerebral palsy, 118, 267
- cerebral venous thrombosis, 194–6
- cesarean section, 184, 186
- childcare/parenting, 246–9
 - family involvement, 248–9
 - knowledge about, 242–3
 - safety, 152, 244–8
- children of women with epilepsy, *See also* infants; neonates
 - cognitive outcomes. *See* cognitive outcomes in offspring
 - epilepsy risk, 6–7, 143–4, 183
 - follow-up, 256–7
 - maternal neuroimaging and, 190–2
- children with epilepsy, female, 6–8
 - adverse effects of AEDs, 93–4
 - bone health, 95, 266–7
 - endocrine effects of AEDs, 94–5
 - psychosocial issues, 95–7
 - seizure control, 95
- choriocarcinoma, metastatic, 199–200
- clefts, oral/facial, 160, 162–3
- clobazam
 - breastfeeding mothers, 229, 236
 - catamenial epilepsy, 107–8
 - contraceptive interactions, 135
 - intrapartum therapy, 177, 186
 - pharmacokinetics, 225
- clomiphene citrate, 110, 124–5
- clonazepam
 - breastfeeding mothers, 229, 236
 - pharmacokinetics, 225
- cognitive adverse effects of AEDs, 94
- cognitive impairment (mental retardation), 96
 - bone health and, 267
 - role in infertility, 116, 118
- cognitive outcomes in offspring
 - breastfeeding and, 14, 149
 - fetal AED exposure, 12, 147, 162, 256–7
 - folic acid supplements and, 148
 - seizures during pregnancy and, 149
- combined hormonal contraception, 131–2
- combined oral contraceptive pill (COC), 131, *See also* oral contraceptives
- comorbidities, 4–6
- computed tomography (CT), 189–90, 201
 - pregnancy-related conditions, 192, 195, 198
 - safety of unborn child, 190–1
- congenital malformations, 159–67, *See also* teratogenicity of AEDs
 - AED dose effects, 146
 - AED polytherapy vs. monotherapy, 147

- AED-related risks, 11–12, 144–8, 159–67
- antenatal screening, 185
- folic acid supplements and, 10–11, 148
- late diagnosis, 256
- major syndromes, 161
- neonatal examination, 253–4
- recurrence risks, 165
- related to specific AEDs, 255
- worldwide registries, 144, 165–6
- contraception, 10, 127–38
- adolescent girls, 95
- AED interactions, 10, 128, 132–7
- clinical recommendations, 135–6
- dual method, 129
- frequency of use, 128
- methods, 128–32
- preconception planning, 138
- role in seizure control, 137–8
- contraceptive implants, 129–30, 137
- contrast media
- pregnant and lactating women, 201–2
- safety of fetus/neonate, 190–2
- cooking safety, 247
- copper intrauterine devices (IUDs), 129–30, 136
- cosmetic adverse effects of AEDs, 93
- curare, 210–11
- cytochrome P450 enzymes, 227
- cytokines, inflammatory, 266
- danazol, 111
- daytime sleepiness, excessive (EDS), 40–1, 47
- DCX gene mutations, 84
- dehydroepiandrosterone sulfate (DHEAS), 62, 70
- depot-medroxyprogesterone acetate (DMPA) (Depo-Provera)
- catamenial epilepsy, 109, 137
- contraception, 130–1, 136
- depression, 4–5, 20–3
- childhood/adolescent epilepsy, 96
- interictal, 21–2
- postpartum (PPD), 5, 22–3
- preictal, ictal, and postictal, 21
- role in infertility, 117
- desflurane, 210
- diabetes mellitus (DM), type 2, 72–3
- diazepam, 209, 216
- diffuse epilepsies, 36
- dihydrotestosterone, 61
- domperidone, 240
- driving, new mothers, 248
- drowning risk, 172
- eclampsia
- difficult intubation, 207
- neuroimaging, 192–4
- postpartum, 220
- electrolyte disturbances, obstetric patients, 208
- endotracheal intubation, obstetric patients, 207
- energy metabolism, effects of AEDs, 71–4
- enflurane, 210
- environmental safety, new mothers, 248
- enzyme-inducing antiepileptic drugs (EIAEDs)
- contraceptive interactions, 10, 132–5
- contraceptive selection, 135–6
- effects on bone health, 270
- obstetric anesthesia and, 208
- psychotropic drug interactions, 30–2
- reproductive endocrine effects, 61–2, 66, 69–70, 121
- thyroid function effects, 74–5
- epidemiology, epilepsy, 1–4
- epidural anesthesia, obstetric, 177, 208
- local anesthetic toxicity, 209
- epilepsy and mental retardation limited to females (EFMR), 84–5
- epilepsy surgery
- mania after, 25
- menstrual cycle changes after, 120
- psychosis after, 26
- epilepsy syndromes
- hereditary, 8, 80–7
- influencing fertility, 118
- estrogen, 51–6
- catamenial epilepsy and, 55–6, 104
- effects of AEDs, 61–2
- effects on bone, 265
- mechanisms of
- neuroexcitatory effects, 51–3, 62, 260–1
- neuroprotective effects, 53–5
- perimenopausal changes, 260
- proconvulsant effects, 52–6
- seizure susceptibility and, 54–6
- sleep effects, 38–9
- testosterone conversion to, 61
- estrogen receptors (ER), 52
- ethosuximide
- breastfeeding mothers, 229, 236–7
- pharmacokinetics, 177, 225
- etomidate, 210
- excessive daytime sleepiness (EDS), 40–1, 47
- Exposure Index, 228–35
- falls, 266
- family support, new mothers, 248–9
- felbamate
- breastfeeding mothers, 229, 237
- contraceptive interactions, 134
- induced weight loss, 73
- pharmacokinetics, 225
- fentanyl, 211–13
- fertility rates, 9, 114–15, *See also* infertility
- fetal anticonvulsant syndrome, 161
- fetal growth restriction, 254
- fetal hydantoin syndrome, 161
- fetus, *See also* congenital malformations; infants
- adverse effects of AEDs, 11–12, 183–4, 252, 256–7
- monitoring, 184–7
- safety of maternal
- neuroimaging, 190–2
- fluid intake, new mothers, 247
- folic acid
- supplementation, 10–11, 148, 185
- valproate interactions, 159

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

278

Index

- follicle-stimulating hormone (FSH), 67–8, 103
- forced normalization, 26
- FOXG1* gene mutations, 80, 82–3
- fracture risk assessment tool (FRAX), 270–1
- fractures, 15, 266
- GABA (γ -aminobutyric acid), estrogen actions, 52–3
- GABA-A receptors
neurosteroid interactions, 59–60
progesterone actions, 57–8, 60, 104
- gabapentin
bone health effects, 268
breastfeeding mothers, 229, 237
induced weight gain, 72
pharmacokinetics, 177, 225
postpartum period, 217, 220
teratogenicity, 11–12, 163
- gadolinium-based contrast media, 191–2, 201–2
- ganaxolone, 110
- gender differences
childhood/adolescent epilepsy, 7
epilepsy risk, 4
- genetic causes of epilepsy in women, 8, 80–7
- genetics, epilepsy, 6–7, 143–4
- glioblastoma multiforme, 199
- glucose metabolism, effects of AEDs, 71–4
- glucuronosyltransferases (UGT), 228
- glutamate, 52
- glutamic acid decarboxylase (GAD), 53, 55
- gonadotropin-releasing hormone (GnRH)
analogs, catamenial epilepsy, 111
pulsatile secretion, 67, 93, 103
- goserelin, 111
- halothane, 210
- head growth, poor fetal, 254
- HELLP syndrome, 194
- hemorrhagic disease of newborn, 187, 253
- heritability, epilepsy, 143–4, 183
- hippocampus, estrogen actions, 52–4
- home environment, safety, 248
- hormonal contraceptives, 129–32
AED interactions, 10, 128, 132–7
catamenial epilepsy, 108–9, 137–8
- hormonal therapy, catamenial epilepsy, 108–11
- hormone replacement therapy (HRT), 14, 262
effects on sleep, 45–6
seizure frequency and, 262
- hormones, 50–62
AEDs and, 61–2, 65–76
catamenial epilepsy and, 55–6, 59, 61, 104–5
effects on sleep problems, 38–40
epilepsy in adolescent girls and, 92–3
influences on brain activity, 51–61
perimenopausal changes, 260
- household chores, 247
- hydration, new mothers, 247
- hydromorphone, 211–13
- hyperandrogenism, 67–9
- hypercarbia, obstetric patients, 208
- hyperinsulinemia, 68–9, 72, 122
- hyperparathyroidism, 270–1
- hyperprolactinemia, 119
- hyperventilation, obstetric patients, 208
- hypoandrogenism, 69–70
- hypocarbica, obstetric patients, 208, 210
- hypoglycemia
neonatal, 256
obstetric patients, 208
- hyponatremia, 75–6
- hypothalamic hypogonadism (hypothalamic amenorrhea), 9, 70, 119
- hypothalamic-pituitary-ovarian (or gonadal) axis, 103
effects of AEDs, 68, 121
effects of epileptic lesion, 67, 119–20
- hypoxia, 207–8
- implants, contraceptive, 129–30, 137
- inadequate luteal phase (ILP) (anovulatory cycles), 102–3, 106–7
- incidence, epilepsy, 2–3
- infant dose, 226, 229
maternal weight-adjusted, 226, 229
- infants, *See also* children of women with epilepsy; neonates
assessing AED exposure, 224–35
determinants of drug exposure levels, 226–35
drug clearance, 227–8
drug exposure indices, 226–7, 229
- infertility, 113–25
epidemiology, 9, 114
etiology, 8–10, 116–22
evaluation, 122–4
management, 123–5
role of AEDs, 66, 120–2
- inheritance, 6–7
- insomnia, 41, 45
- insulin resistance, 68–9, 72, 122
- insulin-like growth factor-1 (IGF-1), 68
- interictal discharges, sleep influences on, 37
- interictal dysphoric disorder, 21–2
- intracranial hemorrhage, neonates, 254
- intrapartum management, 186
- intrauterine devices (IUDs), 129–30
recommendations on use, 136
- intrauterine growth restriction, 254
- iodinated contrast media, 190–1, 201–2
- iron deficiency, 42, 44
- isoflurane, 210
- juvenile absence epilepsy (JAE), 7
- juvenile myoclonic epilepsy (JME), 7, 86
preconception planning, 150, 175
- ketamine, 210

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

- labor and delivery
management, 186
seizure management, 177
seizures during, 173, 208
- lactation. *See* breastfeeding
- lamotrigine (LTG; LMT)
adverse effects in children/
adolescents, 93
bone health effects, 268
breastfeeding mothers, 229,
237
contraceptive interactions,
135–6
dose in pregnancy, 172
kinetics during pregnancy,
177, 179–80
perimenstrual changes in
serum levels, 105–6
pharmacokinetics, 225
postpartum period, 217
reproductive endocrine
effects, 69
teratogenicity, 11–12, 146, 163
- leptin, 265–6
- levetiracetam (LEV)
bone health effects, 269
breastfeeding mothers, 229,
238
cognitive effects of fetal
exposure, 147
hyponatremia/SIADH due
to, 76
kinetics during pregnancy,
177, 179
pharmacokinetics, 225
postpartum period, 217–18
reproductive endocrine
effects, 69
teratogenicity, 11–12, 146,
163–4
- levonorgestrel-releasing
intrauterine device (LNG
IUD), 129–30, 136
- libido, reduced. *See* sexual
dysfunction
- lithium, 30
- local anesthetics, obstetric
patients, 209
- long-acting reversible
contraception (LARC)
methods, 129–31
- lorazepam, 216
- low birth weight infants, 174–5
- luteinizing hormone (LH),
67–8, 103
pulsatile secretion, 119–20
- magnesium sulfate, 177
- magnetic resonance imaging
(MRI), 200–1
pregnancy-related
conditions, 192–7,
199–200
pregnant and lactating
women, 201–3
safety of unborn child, 191–2
- Mallampati classification, 207
- mania
post-epilepsy surgery, 25
postictal, 25
- marriage rates, 9–10, 116
- maternal weight-adjusted
infant dose, 226, 229
- meal preparation, 247
- MeCP2 gene, 80, 82
- medroxyprogesterone acetate
(MPA)
catamenial epilepsy, 109, 137
depot. *See* depot-
medroxyprogesterone
acetate
- meningioma, 199
- menopause, 14–15, 260–2,
See also hormone
replacement therapy
age at, 260
management, 262
premature, 119, 262
seizures at, 261
sleep problems, 44–5
- menstrual cycle, 101–4, *See also*
catamenial epilepsy
AED metabolism during,
105–6
after epilepsy surgery, 120
effects on sleep, 39–40
- menstrual disorders, 8–9
- mental retardation.
See cognitive impairment
- meperidine, 211
- metabolic syndrome, 71
- midazolam, 209, 216
- milk-to-plasma drug-
concentration ratio
(MP ratio), 226, 228,
235
- Mini International
Neuropsychiatric
Interview (MINI), 27
- miscarriage (spontaneous
abortion), 11, 174
- mood changes, new mothers,
246
- mood disorders, 4–5, 20–5
- morphine, 211–13
- muscle relaxants.
See neuromuscular
blocking agents
- myelomeningocele, 185–6
- myopia, in offspring, 256
- neonates, 251–7, *See also*
infants
AED withdrawal symptoms,
256
benzodiazepine withdrawal
syndrome, 209, 236
delivery room care, 253
drug clearance, 227–8
feeding, 247
immediate care and pre-
discharge assessment,
254–6
long-term follow-up, 256–7
opioid withdrawal syndrome,
212, 236
parenting safety, 152, 244–9
physical examination, 253–4
potential complications,
183–4, 253–6
vitamin K supplements, 187,
253
- neuraxial anesthesia, obstetric,
208–9
- neurodevelopmental outcomes.
See cognitive outcomes in
offspring
- neuroimaging in pregnancy,
189–203
brain tumors, 197–200
cerebral venous thrombosis,
194–6
modalities, 189–90
other conditions, 199–200
postpartum cerebral
angiopathy, 197–8
pre-eclampsia and eclampsia,
192–4
recommended protocol,
200–1
safety of unborn child,
190–2
- neuromuscular blocking agents,
208, 210–11
- neuropeptide Y (NPY), 53, 55
- neurosteroids
endogenous, 53–60, 62
therapy, catamenial epilepsy,
110

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

280

Index

- non-rapid eye movement (NREM) sleep, 35, 37
- norepinephrine, 265
- obesity, 68, 121–2, *See also* weight gain
- obstetric anesthesia, 206–13
AED interactions, 208–9
airway management, 207–8
anesthetic induction agents, 209–10
neuromuscular blocking agents, 208, 210–11
opioid analgesics, 211–13
volatile anesthetics, 210
- obstetric monitoring, 184–7
- obstructive sleep apnea (OSA), 6, 41–2, 44–5
- offspring of women with epilepsy. *See* children of women with epilepsy
- opioid analgesics, 211–13
- opioid withdrawal syndrome, neonatal, 212, 236
- oral contraceptives (OC), 10, 131–2
adolescent girls, 95
AED interactions, 132–6
catamenial epilepsy, 109, 138
recommendations on use, 135
- oral/facial clefts, 160, 162–3
- osmolarity, serum, effects of AEDs, 75–6
- osteoporosis, 15, 268
- ovulation, measuring, 107
- oxcarbazepine (OXC)
bone health effects, 269
breastfeeding mothers, 229, 238
contraceptive interactions, 134, 136
hyponatremic effects, 75
kinetics during pregnancy, 177, 179
pharmacokinetics, 225
postpartum period, 218, 220
teratogenicity, 11–12, 164
thyroid function effects, 74–5
- pancuronium, 210–11
- panic disorder, 5–6
- parathyroid hormone (PTH), 265
- parenting. *See* childcare/parenting
- PCDH19* gene mutations, 85
- perimenopause, *See also* hormone replacement therapy
hormonal changes, 260
management, 262
seizures at, 261
- perinatal death, 184
- periodic limb movement disorder (PLMD), 42–3
- periodic limb movements of sleep (PLMS), 42, 44
- pethidine (meperidine), 211
- phenobarbital (PB)
bone health effects, 269–70
breastfeeding mothers, 229, 238
contraceptive interactions, 133
kinetics during pregnancy, 177
metabolism in infants, 227
pharmacokinetics, 225
postpartum period, 218
reproductive endocrine effects, 66, 69–70
teratogenicity, 146, 162
- phenytoin (PHT)
bone health effects, 269–70
breastfeeding mothers, 229, 239
contraceptive interactions, 134
cosmetic adverse effects, 93
inhibition of ADH release, 75
kinetics during pregnancy, 177
metabolism in infants, 227
perimenstrual changes in metabolism, 105
pharmacokinetics, 225
postpartum period, 219
reproductive endocrine effects, 66, 69–70
thyroid function effects, 74
- polycystic ovary syndrome (PCOS), 9, 66–9, 92–3, 118
- polysomnography (PSG), 42, 47
- polytherapy
congenital malformation risk, 147
seizure risk in pregnancy, 171
- post-epilepsy surgery mania, 25
- post-epilepsy surgery psychosis, 26
- posterior reversible encephalopathy syndrome (PRES), 192–4
- postmenopausal women, bone health, 268
- postpartum blues, 22
- postpartum cerebral angiopathy, 197–8
- postpartum depression (PPD), 5, 22–3
- postpartum period, 215–21,
See also breastfeeding; neonates
kinetics of individual AEDs, 216–20
problem of seizure control, 215
recommendations for seizure control, 220
safety considerations, 242–9
status epilepticus, 220
treating breakthrough seizures, 216
treating refractory seizures, 220
vitamin K supplements, 187, 253
- postpartum psychosis (PPP), 22–3
- pre-eclampsia, 12–13, 184
difficult intubation, 207
neuroimaging, 192–4
- preconception counseling, 10–11, 141–53
AED management, 138, 150–2, 175
approach to, 141–2
common questions asked, 143–50
key elements, 141–2
safety and social support, 152
- pregabalin
induced weight gain, 72
kinetics during pregnancy, 177, 179
- pregnancy, 12–14, 170–80, 182–7
adverse effects of seizures, 149, 174–5
adverse outcomes, 12–13, 183–4
AED management, 175, 184

Cambridge University Press

978-1-107-55369-9 - Women with Epilepsy: A Practical Management Handbook

Edited by Esther Bui and Autumn Klein

Index

[More information](#)

- AED pharmacokinetics, 177–80
- antenatal management, 184–6
- incidence of AED use, 251
- neuroimaging in, 189–203
- obstetric and fetal monitoring, 184–7
- postnatal management, 14, 187
- psychotropic drugs, 30–1
- registers, 144, 165–6
- risks of AEDs, 144–8, 157–67, 183–4
- seizure frequency, 148–9, 170–2, 182–3
- seizure management, 13–14, 177
- sleep problems, 43–4
- status epilepticus, 172–3
- pregnenolone sulfate, 59–60
- premature ovarian failure (POF), 119, 262
- premenstrual dysphoric disorder (PMDD), 23–4
- pre-term delivery, 12–13, 174–5, 253
- prevalence, epilepsy, 1–2
- primidone
 - breastfeeding mothers, 229, 239
 - contraceptive interactions, 134
 - pharmacokinetics, 225
- progesterone, 56–9
 - mechanisms of neuroinhibitory effects, 56–7, 60, 261
- perimenopausal changes, 260
- role in catamenial epilepsy, 59, 104–5
- seizure susceptibility and, 58–9
- sleep effects, 39
- therapy, catamenial epilepsy, 109–10, 138
- progesterone receptors (PR), 56–7, 60
- progestin-only pill (POP), 131
- prolactin, 118–19, 265
- propofol, 210
- psychiatric comorbidities, 4–6, 20–32
 - children and adolescents, 94, 96
- psychogenic non-epileptic seizures (PNES), 27–8
- psychosis, 25–6
 - alternative, 26
 - interictal, 26
 - post-epilepsy surgery, 26
 - postpartum, 22–3
 - preictal, postictal, and ictal, 25–6
- psychosocial issues, childhood/adolescent epilepsy, 95–7
- psychotropic drugs
 - AED interactions, 30–2
 - in pregnancy and lactation, 30–1
 - seizure risks, 28–9
- quality of life, childhood/adolescent epilepsy, 97
- radiation exposure, fetus/embryo, 190
- rapid eye movement (REM) sleep, 35–6
- 5 α -reductase, 104
- regional anesthesia, obstetric, 208–9
- remifentanyl, 211–13
- reminders, medication, 245
- renal function, neonates, 228
- reproductive dysfunction, 8–10
 - adolescent girls, 92–3
 - AED selection and, 123–5
 - as cause of infertility, 118–19
 - regular monitoring, 124
 - role of AEDs, 9, 65–71
 - signs and evaluation, 122–4
- respiratory distress, neonatal, 253
- restless legs syndrome (RLS), 42–4
- Rett syndrome, 80–3
- risk-taking behavior, 96
- rocuronium, 210–11
- rufinamide, contraceptive interactions, 135
- safety considerations
 - childcare/parenting, 152, 244–8
 - neuroimaging in pregnancy, 190–2
- schizophrenia, 26
- seizures
 - adolescent girls with epilepsy, 95
 - adverse effects in pregnancy, 149
- estrogen effects, 54–6
- fetal effects, 174–5
- fracture risk, 266
- frequency in pregnancy, 148–9, 170–2, 182–3
- management in pregnancy, 13–14, 177
- menopause/perimenopause, 261
- neonatal, 254
- peripartum, 173
- postpartum management, 216, 220
- postpartum triggers, 245–6
- psychogenic non-epileptic seizures (PNES), 27–8
- self-management, 243–5
- sleep disruption, 37–8
- sleep-wake timing, 36–7
- self-management, postpartum period, 242–9
 - common needs, 243
 - defined, 243
 - medication management, 245
 - seizure management, 243–5
 - seizure triggers, 245–6
- serotonin, 266
- sevoflurane, 210
- sex hormone-binding globulin (SHBG), 66, 70
- sex steroid hormones. *See* estrogen; progesterone; testosterone
- sexual dysfunction, 8, 70
 - as cause of infertility, 117, 120
- sexually transmitted infections, 132
- sleep, 34–40
 - epilepsy interactions, 36–8
 - hormonal influences, 38–40
 - physiology of epilepsy interactions, 35–6
 - stages, 35
- sleep deprivation
 - EEG, 37
 - effects, 40–1
 - new mothers, 245–7
- sleep epilepsies, 36
- sleep-disordered breathing, 41–5
- sleep-related comorbidities, 6, 40–7
- small for gestational age (SGA), 13, 174–5, 183–4

282	Index	
	social factors, leading to infertility, 116	
	social support, new mothers, 152, 245	
	sodium	
	homeostasis, effects of AEDs, 75–6	
	serum level monitoring, 76	
	spina bifida, 160, 162	
	antenatal screening, 185–6	
	status epilepticus	
	antenatal management, 177	
	induction of anesthesia, 209–10	
	postpartum, 220	
	risk during pregnancy, 172–3	
	stigma, as cause of infertility, 116	
	stress, new mothers, 245–6	
	subcortical band heterotopia (SBH), 83–4, 144	
	sudden unexpected death in epilepsy (SUDEP), 36–7, 172	
	sufentanyl, 211–13	
	suicide, 26–7	
	children and adolescents, 94, 96	
	syndrome of inappropriate antidiuretic hormone (SIADH), 76	
	temporal lobe epilepsy (TLE)	
	catamenial epilepsy, 107	
	hypothalamic hypogonadism, 9, 119	
	infertility, 118	
	PCOS association, 67	
	reproductive disorders, 66	
	sexual dysfunction, 8, 70	
	teratogenesis, principles, 158	
	teratogenicity of AEDs, 11–12, 157–67, <i>See also</i>	
	congenital malformations	
	categories of risk, 159–60	
	dose effects, 146	
	folic acid supplements and, 10–11, 148	
	newer AEDs, 159	
	older AEDs, 158–9	
	polytherapy vs. monotherapy, 147	
	preconception counseling, 144–8	
	teratology, 157–8	
	termination of pregnancy, 116	
	testosterone	
	effects on sleep, 39	
	mechanism of effects on brain, 53–60, 62	
	therapeutic drug monitoring (TDM)	
	postpartum period, 216, 220	
	preconception planning, 150–2	
	pregnancy, 175, 180	
	thrombotic thrombocytopenic purpura (TTP), 194	
	thyroid hormones, effects of AEDs, 74–5, 94	
	tiagabine	
	breastfeeding mothers, 229, 239	
	pharmacokinetics, 177, 225	
	topiramate	
	bone health effects, 269	
	breastfeeding mothers, 229, 239	
	cognitive adverse effects, 94	
	contraceptive interactions, 134	
	induced weight loss, 72–3	
	kinetics during pregnancy, 177, 179	
	pharmacokinetics, 225	
	postpartum period, 219–20	
	teratogenicity, 11–12, 146, 162	
	transition to adult care, 97	
	trimethadione syndrome, 161	
	triptorelin, 111	
	ultrasonography, antenatal, 185	
	vagus nerve stimulator (VNS), 220	
	valproic acid (VPA)	
	adverse effects in children/adolescents, 93	
	bone health effects, 269–70	
	breastfeeding mothers, 229, 239–40	
	cognitive effects of fetal exposure, 12, 147, 162, 257	
	contraceptive interactions, 136	
	during pregnancy, 184	
	fertility effects, 121–2	
	hyponatremia/SIADH due to, 76	
	hypothalamic hypogonadism due to, 70	
	induced weight gain, 68–9, 71–4	
	kinetics during pregnancy, 177–9	
	mechanism of teratogenesis, 159	
	PCOS association, 9, 66–9, 93	
	perimenstrual changes in serum levels, 105–6	
	pharmacokinetics, 225	
	postpartum period, 219	
	preconception planning, 150	
	sexual dysfunction due to, 71	
	teratogenicity, 11, 146–7, 162–3	
	use in women of reproductive age, 69	
	vecuronium, 210–11	
	vigabatrin	
	breastfeeding mothers, 229, 240	
	induced weight gain, 72	
	kinetics during pregnancy, 177, 179	
	pharmacokinetics, 225	
	vitamin D, 265, 270–1	
	vitamin K, 187, 253	
	volatile anesthetic agents, 210	
	water balance	
	catamenial epilepsy and, 105	
	effects of AEDs, 75–6	
	weight gain	
	AEDs inducing, 71–2, 94–5, 121–2	
	pregnancy-related, difficult airway, 207	
	valproate-induced, 68–9, 71–4	
	weight loss, AEDs inducing, 72–3	
	zonisamide	
	bone health effects, 269	
	breastfeeding mothers, 229, 240	
	induced weight loss, 73	
	kinetics during pregnancy, 177, 179	
	pharmacokinetics, 225	
	teratogenicity, 164	